<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411823</url>
  </required_header>
  <id_info>
    <org_study_id>19-000348</org_study_id>
    <nct_id>NCT04411823</nct_id>
  </id_info>
  <brief_title>Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction</brief_title>
  <official_title>Prediction of Post-laparoscopic Sleeve Gastrectomy Gastroesophageal Reflux Disease With an Endolumenal Functional Lumen Imaging Probe (EndoFLIP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to identify predictors for gastroesophageal reflux disease after
      sleeve gastrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo an upper endoscopy with EndoFLIP before sleeve gastrectomy to measure
      parameters from endoscopy and EndoFLIP device to develop a prediction model for
      post-operative gastroesophageal reflux disease. Subjects will undergo a repeat upper
      endoscopy with EndoFLIP at 6 months after surgery and complete questionnaires during
      follow-ups up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Worsening or new-onset gastroesophageal reflux disease</measure>
    <time_frame>Baseline, 6 months, and 5 years</time_frame>
    <description>Determined by the change in the GERD-Health Related Quality of Life questionnaire score with questions individually scored on a scale of 0-5, combined to determine a total score range of 0-75 where a higher score indicates worse quality of life and increased score would indicate new or worsening GERD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worsening dysphagia</measure>
    <time_frame>Baseline, 6 months, and 5 years</time_frame>
    <description>Determined by the change in the Brief Esophageal Dysphagia questionnaire score with questions individually scored on a scale 0-5, combined to determine a total score range of 0-40 where a higher score indicates worse dysphagia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <condition>Sleeve Gastrectomy</condition>
  <condition>Bariatric Surgery Complication</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Undergo an upper endoscopy with EndoFLIP at baseline before sleeve gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EndoFLIP measurement</intervention_name>
    <description>EndoFLIP device can measure gastroesophageal junction distensibility index and esophageal contractile pattern. It is performed during endoscopy.</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients &gt; 18 years

          -  BMI over 30 kg/m2 and stable weight for 3 months before the procedure

          -  Participants can give a consent to the procedure

          -  Participants have no contraindications to LSG (anticoagulation, gastric ulceration,
             hiatal hernia of &gt; 5 cm)

        Exclusion Criteria:

          -  Participants who have LA grade C or D esophagitis, Barrett mucosa or peptic stricture.

          -  Patients who have evidence of a major motility abnormality defined by the Chicago
             classification version 3.0 (achalasia, absent contractility, esophagogastric junction
             outflow obstruction, distal esophageal spasm, or hypertensive peristalsis)

          -  Patients with hiatal hernia &gt; 3 cm

          -  Patients with previous esophageal or stomach surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barham Abu Dayyeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barham K. Abu Dayyeh, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal Reflux</keyword>
  <keyword>Sleeve gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

